CYP-004
Osteoarthritis (Knee)
Phase 3Completed (Reported 2022)
Key Facts
Indication
Osteoarthritis (Knee)
Phase
Phase 3
Status
Completed (Reported 2022)
Company
About Cynata Therapeutics
Cynata develops off-the-shelf stem cell therapies using its scalable Cymerus platform to treat inflammatory and ischemic conditions.
View full company profileTherapeutic Areas
Other Osteoarthritis (Knee) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADSC Therapy for Osteoarthritis | A4Cell | Phase 1/2 |